within Pharmacolibrary.Drugs.ATC.N;

model N02CD02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.55,
    Cl             = 0.000135,
    adminDuration  = 600,
    adminMass      = 0.24,
    adminCount     = 1,
    Vd             = 0.0073,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0002666666666666667,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Galcanezumab is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP), a neuropeptide involved in migraine pathophysiology. It is approved for the preventive treatment of migraine in adults and also for the treatment of episodic cluster headache.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic parameters reported for healthy subjects and patients with migraine, both sexes, adults aged 18â€“65 years. Values based on typical 240 mg subcutaneous loading dose followed by 120 mg monthly maintenance doses.</p><h4>References</h4><ol><li><a href='https://dx.doi.org/10.1002/cpt.1060'>10.1002/cpt.1060</a> Pharmacokinetic parameters derived from published clinical pharmacology reviews and a population PK study in healthy subjects and patients with migraine; see PMID: 29778128 and EMA/CHMP/589457/2018 for additional supporting data.</li></ol></body></html>",
    revisions = "<html><body><ul><li>03/06/2025 model generated from PK parameters and knowledge obtained by LLM gpt-4.1 and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N02CD02;
